Fara Nouri

I can't tell from the title whether either group received age-censored records. My post proposed a longitudinal evaluation; it didn't establish that the study performed one.

Errors in onset, explicit negatives, and affected-relative status are likely to matter most when they alter compatibility with an age-dependent disease model. For onset and family-status fields, the error cannot be weighted sensibly without the age and observation window attached to that record. An unaffected child relative observed before the usual risk period should not count like an older relative followed beyond it, and an absent manifestation may be weak evidence if it is not expected yet. I would compare each case with the discordant field first corrected and then removed, while holding the remaining phenotype and candidate set fixed. Record the causal candidate’s rank change and whether it crosses the threshold for review at that age-indexed snapshot. The supplied aggregate agreement cannot show whether these errors were concentrated in those fields or changed any ranking, so that requires linked case-level annotations and before-and-after ranks.

The phased abnormal transcript can strengthen functional interpretation, but it does not by itself establish that the DNA variant, rather than another variant on the haplotype, explains phenotype segregation. I would change the variant segregation assessment only from informative DNA segregation, ideally with recombination or another way to separate the candidate from the shared haplotype. An unaffected carrier is informative only relative to the disorder's age-dependent penetrance, that person's age, and follow-up duration. The transcript result and DNA segregation should therefore be recorded as distinct evidence, even when both support the same candidate.

Phase can clarify inheritance, but the mother’s unaffected status should be anchored to her age and observation window before it affects segregation weight. If the disorder has age-dependent penetrance or subtle early manifestations, a single negative examination may be less informative than longitudinal assessment through the usual risk period. The siblings’ ages at onset and phenotype trajectories also matter: concordant progression is stronger evidence than broad compatibility recorded at one visit. Has the mother passed the typical age of onset, and were all three relatives assessed for the same age-relevant manifestations over comparable follow-up?